NASDAQ$HOWL
Werewolf Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · Investor relations
Briefing
Werewolf Therapeutics reported Q3 2025, net loss of $16.4M.
For Q3 2025, Werewolf Therapeutics reported a net loss of $16.4M. Management discusses segment performance, capital allocation, and outlook in the earnings filing.
- Net loss $16.4M.
- Werewolf Therapeutics highlights liquidity, operations, and 2026 priorities.
- Werewolf Therapeutics highlights liquidity, operations, and 2026 priorities.
Headline financials
Revenue & EPS history
Werewolf Therapeutics · Revenue · Quarterly
$1.3M
Forward guidance
The release discusses Werewolf Therapeutics's outlook for upcoming periods, including capital allocation, operating priorities, and market risks, without relying solely on numeric EPS bridges.
Tailwinds
- Werewolf Therapeutics cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q3 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+0.1%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+2.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+16.5%
Q2 2022
Best reaction
-7.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.5% | -2.3% | -39.8% | |
| Q3 2025 | -5.0% | -7.4% | -22.0% | |
| Q2 2025 | -1.5% | -5.9% | +5.9% | |
| Q1 2025 | +0.9% | -2.7% | +9.9% | |
| Q4 2024 | -0.9% | -3.4% | -21.5% | |
| Q3 2024 | -5.7% | -11.9% | -26.2% | |
| Q1 2024 | -1.6% | -9.9% | -15.0% | |
| Q4 2023 | -7.4% | -6.1% | -15.8% | |
| Q3 2023 | -0.9% | +3.6% | +28.8% | |
| Q2 2023 | +3.2% | -0.8% | -0.4% | |
| Q1 2023 | -3.3% | -9.9% | +11.2% | |
| Q4 2022 | +6.1% | +9.2% | +3.1% | |
| Q3 2022 | +2.3% | -5.0% | -19.4% | |
| Q2 2022 | +16.5% | +21.3% | +55.2% | |
| Q1 2022 | +3.3% | -12.1% | +1.7% | |
| Q4 2021 | +0.5% | +9.5% | +12.6% | |
| Q3 2021 | +1.8% | +1.6% | -6.7% | |
| Q3 2020 | +1.8% | +1.6% | -6.7% | |
| Q2 2021 | -3.5% | -2.7% | +13.9% | |
| Q2 2020 | -3.5% | -2.7% | +13.9% | |
| Q1 2021 | +1.0% | +5.8% | +22.4% | |
| Q1 2020 | +1.0% | +5.8% | +22.4% | |
| Q4 2020 | +1.0% | +5.8% | +22.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro